Obesity is the leading risk factor for type 2 diabetes. Obesity causes increased levels of fatty acids and inflammation, leading to insulin resistance. In this touchENDOCRINOLOGY interview, Prof. Timothy Garvey (University of Alabama, Birmingham, AL, USA) discusses this risk of developing type 2 diabetes in people with obesity.
The abstract entitled: ‘Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
- What is known about the risk of developing type 2 diabetes in people with obesity? (0:22)
Disclosures: Timothy Garvey discloses grant/research support from Eli Lilly, Epitomee, Novo Nordisk, Pfizer.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The Role of Semaglutide in the Treatment Paradigm for Prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs Liraglutide 3.0 mg on Glucose Metabolism – STEP 8 Post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 Agonists and Other Emerging Treatments of Obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!